Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    17909360 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
Conditions: Lung Cancer;   Esophageal Cancer;   Malignant Pleural Mesothelioma;   Sarcoma;   Thymic Carcinoma
Interventions: Biological: Allogeneic Tumor Cell Vaccine (K562);   Drug: Celecoxib;   Drug: cyclophosphamide

Indicates status has not been verified in more than two years